On February 1st, Red Star Capital Bureau reported that Novo Nordisk (NVO.US) released its 2023 annual report, which showed that the company's annual revenue was approximately DKK 232.261 billion (approximately USD 33.771 billion), a year-on-year increase of 31%; The operating profit was approximately DKK 102.574 billion (approximately USD 14.914 billion), a year-on-year increase of 37%; The net profit was approximately 83.683 billion Danish kroner (approximately 12.1 billion US dollars), a year-on-year increase of 51%.
Screenshots taken from the same flower order
According to business division, the total revenue of diabetes and obesity care business was about DKK 215.098 billion (about USD 31.275 billion), up 38% year on year. Among them, the revenue of GLP-1 diabetes products was about DKK 12.3132 billion (about US $17.8 billion), up 48% year on year; The revenue from obesity care products is approximately DKK 41.632 billion (approximately USD 6.053 billion), a year-on-year increase of 147%.
However, revenue from rare disease products has declined year-on-year. The total revenue was approximately DKK 17.163 billion (approximately USD 2.496 billion), a year-on-year decrease of 16%.
Looking at different regions, China's total revenue is approximately 16.687 billion Danish kroner (approximately 2.426 billion US dollars), a year-on-year increase of 3%. The revenue from GLP-1 products is 6.208 billion Danish kroner (approximately 903 million US dollars), accounting for 76.6% of the market share in China.
Screenshots taken from the same flower order
Smeglutide, as the most popular product of Novo Nordisk in recent years, currently includes three products, namely injection Ozempic (indication for type 2 diabetes), injection Wegovy (indication for obesity) and tablet Rybelsus (indication for type 2 diabetes).
Among them, Ozempic's sales were approximately 95.718 billion Danish kroner (approximately 13.917 billion US dollars), a year-on-year increase of 60%; Wegovy's sales were approximately 31.343 billion Danish kroner (approximately 4.557 billion US dollars), a year-on-year increase of 407%; Rybelsus sold approximately 18.75 billion Danish kroner (approximately 2.726 billion US dollars), a year-on-year increase of 66%.
In addition, looking ahead to 2024, Novo Nordisk is expected to see sales growth of 18% -26% and operating profit growth of 21% -29%.
转播
